NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free MRSN Stock Alerts $4.48 -0.01 (-0.22%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.47▼$4.7150-Day Range$2.71▼$5.9452-Week Range$0.80▼$9.62Volume1.40 million shsAverage Volume2.36 million shsMarket Capitalization$543.42 millionP/E RatioN/ADividend YieldN/APrice Target$6.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Mersana Therapeutics alerts: Email Address Mersana Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside40.3% Upside$6.29 Price TargetShort InterestBearish7.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment0.64Based on 3 Articles This WeekInsider TradingSelling Shares$127,663 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.56 out of 5 starsMedical Sector105th out of 938 stocksPharmaceutical Preparations Industry38th out of 423 stocks 4.4 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.29, Mersana Therapeutics has a forecasted upside of 40.3% from its current price of $4.48.Amount of Analyst CoverageMersana Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.20% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mersana Therapeutics has recently increased by 22.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMersana Therapeutics has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mersana Therapeutics is -0.69. Previous Next 2.6 News and Social Media Coverage News SentimentMersana Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.Search Interest15 people have searched for MRSN on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,663.00 in company stock.Percentage Held by Insiders12.50% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 14.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Mersana Therapeutics Stock (NASDAQ:MRSN)Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Read More MRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRSN Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 20, 2024 | americanbankingnews.comJPMorgan Chase & Co. Upgrades Mersana Therapeutics (NASDAQ:MRSN) to "Neutral"March 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 ExpertsMarch 1, 2024 | seekingalpha.comMersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | nasdaq.comGuggenheim Upgrades Mersana Therapeutics (MRSN)March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming MilestonesMarch 1, 2024 | msn.comTruist Securities Upgrades Mersana Therapeutics (MRSN)March 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 1, 2024 | msn.comWedbush Upgrades Mersana Therapeutics (MRSN)February 29, 2024 | markets.businessinsider.comExpert Outlook: Mersana Therapeutics Through The Eyes Of 5 AnalystsFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | realmoney.thestreet.comGuggenheim gets more bullish on Mersana Therapeutics, upgrades sharesFebruary 29, 2024 | finance.yahoo.comAn Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% UndervaluedFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics Full Year 2023 Earnings: Revenues DisappointFebruary 29, 2024 | finance.yahoo.comQ4 2023 Mersana Therapeutics Inc Earnings CallFebruary 28, 2024 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | msn.comMersana Therapeutics GAAP EPS of -$0.16 in-line, revenue of $10.7M misses by $4.07MFebruary 28, 2024 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | finance.yahoo.comMersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | markets.businessinsider.comHere's what Wall Street expects from Mersana Therapeutics's earningsFebruary 27, 2024 | msn.comMersana Therapeutics Q4 2023 Earnings PreviewFebruary 27, 2024 | globenewswire.comMersana Therapeutics to Present at Upcoming Investor ConferencesFebruary 27, 2024 | benzinga.comMersana Therapeutics Stock (NASDAQ:MRSN) Dividends: History, Yield and DatesFebruary 21, 2024 | finance.yahoo.comMersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024February 21, 2024 | globenewswire.comMersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024See More Headlines Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees123Year FoundedN/APrice Target and Rating Average Stock Price Target$6.29 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+40.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-171,670,000.00 Net Margins-465.80% Pretax Margin-465.80% Return on Equity-282.36% Return on Assets-62.64% Debt Debt-to-Equity Ratio0.63 Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual Sales$36.85 million Price / Sales14.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book14.45Miscellaneous Outstanding Shares121,300,000Free Float106,140,000Market Cap$543.42 million OptionableOptionable Beta1.53 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Martin H. Huber M.D. (Age 63)President, CEO & Director Comp: $44kMr. Brian C. DeSchuytner (Age 45)Senior VP, CFO & COO Comp: $626.32kDr. Timothy B. Lowinger Ph.D. (Age 60)Senior VP, Chief Science & Technology Officer Comp: $666.3kMs. Alejandra Veronica Carvajal J.D. (Age 50)SVP, Secretary & Chief Legal Officer Comp: $606.51kMr. Mikhail Papisov Ph.D.Co-FounderMr. Ashish Mandelia (Age 49)VP, Controller & Chief Accounting Officer Mr. Jason FredetteSenior Vice President of Investor Relations & Corporate CommunicationsMr. Chuck MillerSenior Vice President of Regulatory AffairsMr. Marc DamelinExe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.Dr. Tushar Misra Ph.D. (Age 64)SVP & Chief Manufacturing Officer Comp: $485.89kMore ExecutivesKey CompetitorsPhibro Animal HealthNASDAQ:PAHCIGM BiosciencesNASDAQ:IGMSBiomea FusionNASDAQ:BMEAEsperion TherapeuticsNASDAQ:ESPRLyell ImmunopharmaNASDAQ:LYELView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 51,465 shares on 3/11/2024Ownership: 5.142%Goldman Sachs Group Inc.Sold 191,488 shares on 3/1/2024Ownership: 0.121%American International Group Inc.Bought 2,588 shares on 2/28/2024Ownership: 0.046%Readystate Asset Management LPBought 295,038 shares on 2/20/2024Ownership: 0.244%Price T Rowe Associates Inc. MDSold 12,143 shares on 2/16/2024Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions MRSN Stock Analysis - Frequently Asked Questions Should I buy or sell Mersana Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRSN shares. View MRSN analyst ratings or view top-rated stocks. What is Mersana Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued 12 month price targets for Mersana Therapeutics' stock. Their MRSN share price targets range from $5.00 to $9.00. On average, they anticipate the company's stock price to reach $6.29 in the next twelve months. This suggests a possible upside of 40.3% from the stock's current price. View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts. How have MRSN shares performed in 2024? Mersana Therapeutics' stock was trading at $2.32 at the beginning of the year. Since then, MRSN shares have increased by 93.1% and is now trading at $4.48. View the best growth stocks for 2024 here. Are investors shorting Mersana Therapeutics? Mersana Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,730,000 shares, an increase of 22.3% from the February 29th total of 7,140,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover ratio is presently 3.8 days. View Mersana Therapeutics' Short Interest. When is Mersana Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MRSN earnings forecast. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.16) EPS for the quarter, meeting analysts' consensus estimates of ($0.16). The firm had revenue of $10.70 million for the quarter, compared to the consensus estimate of $22.59 million. Mersana Therapeutics had a negative net margin of 465.80% and a negative trailing twelve-month return on equity of 282.36%. The business's revenue for the quarter was down 27.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.44) earnings per share. What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS). When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Balyasny Asset Management L.P. (8.03%), Vanguard Group Inc. (5.17%), Vanguard Group Inc. (5.14%), Nextech Invest Ltd. (4.95%), Affinity Asset Advisors LLC (0.83%) and Northern Trust Corp (0.77%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Lawrence M Alleva, Mohan Bala, Timothy B Lowinger and Tushar Misra. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRSN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.